5-Fluorouracil pharmacogenomics: still rocking after all these years?

Area of Science:

• Pharmacogenomics
• Molecular Biology
• Oncology

Background:

• 5-fluorouracil (5-FU) is a cornerstone chemotherapy drug.
• Its efficacy is influenced by intracellular enzyme activity.
• Key enzymes include thymidylate synthase, methylenetetrahydrofolate reductase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase.

Purpose of the Study:

• To review and synthesize research on enzyme mutations and 5-FU treatment outcomes.
• To highlight the often contradictory findings in the literature.
• To provide a clearer understanding of pharmacogenetic markers for 5-FU therapy.

Main Methods:

• Literature review of studies investigating enzyme mutations and 5-FU sensitivity/resistance.
• Analysis of contradictory results across different research.
• Focus on the roles of specific enzymes in 5-FU metabolism.

Main Results:

• Mutations in key enzymes can alter 5-FU metabolism, affecting drug activation and degradation.
• Studies show conflicting evidence regarding the predictive value of these mutations for treatment response.
• Enzyme activity levels are critical for determining patient sensitivity or resistance to 5-FU.

Conclusions:

• The relationship between enzyme mutations and 5-FU efficacy is complex and often contradictory.
• Further research is needed to reconcile conflicting findings and establish reliable pharmacogenetic biomarkers.
• Understanding these enzymatic pathways is crucial for optimizing 5-FU-based cancer treatments.